FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> cancer vaccine | glioblastoma

UCSF researchers unveil promising glioblastoma vaccine data

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!



Tools

A mid-stage trial of an experimental vaccine for glioblastoma showed that the drug was effective and less toxic that currently-available treatments. The results were unveiled Monday at the annual American Society of Clinical Oncology meeting.

The trial, led by researchers at the University of California, San Francisco Medical Center, included 33 patients with the deadly brain cancer. A unique therapeutic vaccine was crafted for each patient's tumor. Researcher said that without treatment, the patients in their trial would typically die within five to nine months. But the median survival rate for the vaccine group was 11 months, with some surviving over a year. UCSF researchers also observed an immune response in patients who got the vaccine, leading them to believe that survival could be extended by combining their treatment with other drugs for glioblastoma.

"The vaccine induces an immune response against multiple tumor-specific targets that allows patients to fight their own disease," said lead researcher Dr. Andrew Parsa. "The survival data thus far compare favorably with historical controls and clearly support advancement of this vaccine into later-stage randomized trials to directly compare the vaccine's effectiveness to conventional treatment." Parsa's group is working with Lexington, MA-based biotech Agenus, which is planning a randomized Phase II trial of the vaccine.

- here's the article

Related Articles:
Antigenics changes name to Agenus
Personalized cancer vax shows promise against glioblastomas in study
Charity bankrolls brain cancer vaccine trial


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:

More stories about cancer vaccine   glioblastoma